(Q24244633)

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

Objective quantification of spastic hypertonia: correlation with clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

Onset, natural history and outcome in idiopathic adult motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

Altered metabolism of excitatory amino acids, N-acetyl-aspartate and N-acetyl-aspartyl-glutamate in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

Anti-spasticity agents for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

Trial of Baclofen in Amyotrophic Lateral Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

7 January 2021

Protirelin tartrate (TRH-T) in upper motoneuron syndrome: a controlled neurophysiological and clinical study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

7 January 2021

Intrathecal baclofen for intractable spasticity in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

7 January 2021

El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases a

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

7 January 2021

Pendulum testing of spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

7 January 2021

The value of muscle exercise in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

7 January 2021

Intrathecal baclofen for severe spinal spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

7 January 2021

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

7 January 2021

Interrater reliability of a modified Ashworth scale of muscle spasticity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

7 January 2021

The Sickness Impact Profile: Development and Final Revision of a Health Status Measure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

7 January 2021

Familial adult motor neuron disease: amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004156.PUB3

7 January 2021